NHS diagnostic plans rocked by Atos move
This article was originally published in Clinica
Executive Summary
The UK's Department of Health has backtracked on plans involving two major NHS diagnostic service centralisation contracts. Atos Healthcare, a division of Paris-based group Atos Origin, was in line to manage the provision of diagnostic services across the North West and South West regions of the NHS, but the DOH has announced that it has changed its mind, arguing that it "was not in a position to meet the contractual conditions and establish services to the timescales agreed".
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.